← Leaderboards
Annette Marleau
Aethlon Medical, Inc.
$2,771,755
Attributed
$3,085,255
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2017–20$2M$1.5M$1M$500K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$3,085,255 · 4
By mechanism
N44$1,860,561 · 1
U01$627,000 · 1
N43$299,250 · 1
R43$298,444 · 1
Top collaborators
- Theresa L. Whiteside1 shared
Others in their field
Other Emerging Leaders on “Tumor-Derived”
- Hong Chen · Washington University$4,674,283
- Moran Amit · University Of Tx Md Anderson Can Ctr$4,646,876
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$4,604,309
- Yazhen Zhu · University Of California Los Angeles$4,089,586
- Jessie Nedrow · University Of Pittsburgh At Pittsburgh$3,078,685
- Lingtao Jin · University Of Texas Hlth Science Center$2,882,848
Research focus
Tumor-DerivedDevicesExosomeNon-MalignantMalignant NeoplasmsBaseTumorAffinityPlasmaVirusDesignBloodLectinLaboratoriesCancer PatientAgglutininsImmunosuppressionHemofiltrationExperimental StudyFiberClinical CareGalanthus NivalisImmuneBlood Circulation
Grant awards (4)
Depleting exosomes to improve responses to immune therapy in HNSCC$627,000
U01 · FY2020 · DE
Topic 359: A Device Prototype for Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring$1,860,561
N44 · FY2019 · CA · contact PI
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation$298,444
R43 · FY2018 · CA · contact PI
IGF::OT::IGF Phase I SBIR Topic 359 Title: Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes09/15/2017 - 06/14/2018Firm Fixed Price$299,250
N43 · FY2017 · CA · contact PI